Philippe Moreau, MD, is Head of the Hematology Department and the unit for early Phase I/II trials in clinical hematology at the University Hospital of Nantes, Nantes, France. Prof. Moreau previously held the position of University Professor of Clinical Hematology at the Nantes Faculty of Medicine, Nantes, France, as well as being a member of the organizing committee for the 2011 International Myeloma Workshop in Paris. He is a member of the administration council of the Intergroupe Francophone du Myélome (IFM) and was Chair of the IFM from 2006 to 2009.
Prof. Moreau studied medicine at the University of Reims, Reims, France, then later completed his fellowship at the University Hospital of Nantes where also he finished his hematology training. Prof. Moreau has authored over 280 peer-reviewed articles.
Speaking on high-dose therapy and novel agents for multiple myeloma
As a leading researcher in multiple myeloma, Prof. Moreau is the principal investigator on many key clinical trials investigating novel therapies for myeloma. Prof. Moreau played a significant role in the TOURMALINE-MM1 trial which led to the FDA approval of the proteasome inhibitor ixazomib in 2015. He is currently involved in trials for many immunotherapeutic drugs including monoclonal antibody therapies and chimeric antigen receptor (CAR) T-cell therapies.